Global Health Economics, AstraZeneca, Gaithersburg, MD, USA.
Health Economics and Outcomes Research Ltd, Cardiff, UK.
Int J Clin Pract. 2021 Apr;75(4):e13941. doi: 10.1111/ijcp.13941. Epub 2021 Jan 5.
Hyperkalaemia (HK) is associated with increased mortality risk. Prior studies suggest that the causes of HK are multifactorial. This study aimed to examine risk factors for incident and recurrent HK in six large real-world cohorts of UK patients that could be considered at elevated HK risk because of underlying disease pathology and/or medication use.
This retrospective, observational cohort study utilised UK primary and secondary care data from Clinical Practice Research Datalink (CPRD) and linked Hospital Episode Statistics (HES), respectively. Patients were included if they were aged ≥18 years and had a record of ≥1 condition of interest (chronic kidney disease [CKD] stage 3+, heart failure, resistant hypertension [RHTN], dialysis, diabetes) and/or renin-angiotensin-aldosterone system inhibitors (RAASi) use between 01 January 2003 and 30 June 2018. Based on their diagnosis/ RAASi prescription record, patients were assigned to overlapping cohorts. The outcomes assessed were HK and recurrent HK, the latter defined as second or subsequent HK episode during follow-up. HK was defined as a serum K measurement ≥5.0 mmol/L; thresholds of ≥5.5 and ≥ 6.0 mmol/L were also explored.
Of 931 460 meeting the eligibility criteria, 310 535 (33.3%) patients experienced ≥1 HK event and 187 719 (20.2%) experienced HK recurrence. The probability of subsequent HK events increased with event number from 60.5% for the second event to 76.5% for the sixth and the corresponding time to the next HK event decreased from 15.8 months to 6.1 months. Amongst the key risk factors, serum creatinine, serum phosphorus, systolic blood pressure, and white cell count demonstrated direct relationships with incidence and recurrence of HK, while inverse relationships were observed for estimated glomerular filtration rate (eGFR), haemoglobin and diastolic blood pressure. The relationship for Charlson's Comorbidity Index was mixed. The use of RAASi and anti-hyperglycaemic agents was associated with an increased risk of HK, while the use of diuretics (non-K -sparing) was protective against HK.
Several risk factors for HK that are easily measured in routine clinical practice were identified, facilitating the identification of patients who are at the highest risk of experiencing HK, including recurrent HK.
高钾血症(HK)与死亡率风险增加有关。先前的研究表明,HK 的病因是多因素的。本研究旨在检查六个大型英国患者真实世界队列中与 HK 相关的事件和复发性 HK 的危险因素,这些队列可能因潜在疾病病理和/或药物使用而处于 HK 风险升高的状态。
这项回顾性观察性队列研究利用了来自临床实践研究数据链接(CPRD)的英国初级和二级护理数据和相关的住院患者统计数据(HES)。如果患者年龄≥18 岁且有≥1 种感兴趣的疾病(慢性肾脏病[CKD]3+期、心力衰竭、难治性高血压[RHTN]、透析、糖尿病)和/或肾素-血管紧张素-醛固酮系统抑制剂(RAASi)使用记录,从 2003 年 1 月 1 日至 2018 年 6 月 30 日,他们将被纳入研究。根据他们的诊断/RAASi 处方记录,患者被分配到重叠队列中。评估的结果是 HK 和复发性 HK,后者定义为随访期间第二次或随后的 HK 发作。HK 定义为血清 K 测量值≥5.0mmol/L;还探讨了≥5.5 和≥6.0mmol/L 的阈值。
符合入选标准的 931460 名患者中,310535 名(33.3%)患者发生了≥1 次 HK 事件,187719 名(20.2%)患者发生了 HK 复发。随后发生 HK 事件的概率随着事件次数的增加而增加,第二次事件为 60.5%,第六次事件为 76.5%,下一次 HK 事件的时间从 15.8 个月减少到 6.1 个月。在关键危险因素中,血清肌酐、血清磷、收缩压和白细胞计数与 HK 的发生和复发呈直接关系,而估算肾小球滤过率(eGFR)、血红蛋白和舒张压则呈负相关。Charlson 合并症指数的关系是混合的。RAASi 和抗高血糖药物的使用与 HK 风险增加有关,而利尿剂(非 K 保钾)的使用则可预防 HK。
确定了一些在常规临床实践中易于测量的 HK 危险因素,有助于识别发生 HK 风险最高的患者,包括复发性 HK。